Suppr超能文献

黎巴嫩的 SARS-CoV-2 抗体血清阳性率:首次全国血清学调查结果。

SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.

机构信息

General Director of Islamic Health Society, Baabda, Lebanon.

Department of Research, Islamic Health Society, Baabda, Lebanon.

出版信息

BMC Infect Dis. 2022 Jan 10;22(1):42. doi: 10.1186/s12879-022-07031-z.

Abstract

BACKGROUND

Lebanon, a small country in the Middle East, remains severely affected by the COVID-19 pandemic. Seroprevalence surveys of anti-SARS-CoV-2 antibodies provide accurate estimates of SARS-CoV-2 infection and hence evaluate the extent of the pandemic. The present study aimed to evaluate the prevalence of SARS-CoV-2 antibodies in Lebanon and to compare the estimated cumulative number of COVID-19 cases with the officially registered number of laboratory-confirmed cases up to January 15, 2021.

METHODS

A nationwide population-based serosurvey study was conducted in Lebanon between December 7, 2020, and January 15, 2021, before the initiation of the national vaccination program. The nCOVID-19 IgG & IgM point-of-care (POCT) rapid test was used to detect the presence of anti-SARS-COV-2 immunoglobulin G (IgG) in the blood. Seroprevalence was estimated after weighting for sex, age, and area of residence and adjusting for the test performance.

RESULTS

Of the 2058 participants, 329 were positive for IgG SARS-COV-2, resulting in a crude seroprevalence of 16.0% (95% CI 14.4-17.6). The weighed seroprevalence was 15.9% (95% CI of 14.4 and 17.4). After adjusting for test performance, the population weight-adjusted seroprevalence was 18.5% (95% CI 16.8-20.2). This estimate implies that 895,770 individuals of the general population were previously infected by COVID-19 up to January 15, 2021 in Lebanon. The overall estimated number of subjects with previous SARS-CoV-2 infection was three times higher than the officially reported cumulative number of confirmed cases. Seroprevalence was similar across age groups and sexes (p-value > 0.05). However, significant differences were revealed across governorates.

CONCLUSIONS

Our results suggest that the Lebanese population is still susceptible to SARS-CoV-2 infection and far from achieving herd immunity. These findings represent an important contribution to the surveillance of the COVID-19 pandemic in Lebanon and to the understanding of how this virus spreads. Continued surveillance for COVID-19 cases and maintaining effective preventive measures are recommended to control the epidemic spread in conjunction with a national vaccination campaign to achieve the desired level of herd immunity against COVID-19.

摘要

背景

黎巴嫩是中东的一个小国,仍然受到 COVID-19 大流行的严重影响。抗 SARS-CoV-2 抗体的血清阳性率调查提供了对 SARS-CoV-2 感染的准确估计,从而评估了大流行的程度。本研究旨在评估黎巴嫩 SARS-CoV-2 抗体的流行率,并将估计的 COVID-19 累计病例数与截至 2021 年 1 月 15 日官方登记的实验室确诊病例数进行比较。

方法

2020 年 12 月 7 日至 2021 年 1 月 15 日,在全国范围内开展了一项基于人群的血清学调查研究,该研究在全国疫苗接种计划开始之前进行。使用 nCOVID-19 IgG 和 IgM 即时检测(POCT)快速检测试剂盒检测血液中 SARS-CoV-2 免疫球蛋白 G(IgG)的存在。在对性别、年龄和居住地进行加权并调整检测性能后,估计了血清阳性率。

结果

在 2058 名参与者中,有 329 名 IgG SARS-CoV-2 呈阳性,粗阳性率为 16.0%(95%置信区间 14.4-17.6)。加权阳性率为 15.9%(95%置信区间 14.4 和 17.4)。在调整检测性能后,人群加权阳性率为 18.5%(95%置信区间 16.8-20.2)。这一估计意味着,截至 2021 年 1 月 15 日,黎巴嫩一般人群中有 895770 人以前感染过 COVID-19。总体上,以前感染 SARS-CoV-2 的人数估计是官方报告的累计确诊病例数的三倍。血清阳性率在年龄组和性别之间相似(p 值>0.05)。然而,不同省份之间存在显著差异。

结论

我们的研究结果表明,黎巴嫩人口仍易受 SARS-CoV-2 感染,远未达到群体免疫。这些发现为黎巴嫩 COVID-19 大流行的监测以及了解该病毒的传播方式做出了重要贡献。建议继续监测 COVID-19 病例,并在全国疫苗接种运动的同时继续采取有效的预防措施,以控制疫情传播,达到对 COVID-19 的理想群体免疫水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a29/8744316/b51d72da20ff/12879_2022_7031_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验